Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Healthcare

The GLG Healthcare Practice provides access to a global network of more than 55,000 experts from across the entire healthcare industry including physicians, researchers, scientists, and healthcare industry executives.

The Healthcare Practice provides insight into issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors.

Leading Experts on Healthcare

Keith Berman, Consultant, HEALTH RESEARCH ASSOCIATESKeith Berman

Consultant
HEALTH RESEARCH ASSOCIATES
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Keith Berman, MPH, MBA, founded Health Research Associates in 1996. HRA provides reimbursement consulting, business development and market research services to leading biopharmaceuticals, blood products and medical device manufacturers and suppliers....

Louis Rocco

System Director of Purchasing
HALLMARK HEALTH SYSTEM, INC.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Louis Rocco is the System Director of Purchasing at Hallmark Health System, in Massachusetts. He has over 25 years of experience in purchasing and has negotiation, analytical, reporting and communication skills in inventory, distribution, purchasing,...

Adam Fein, Founder & President, PEMBROKE CONSULTING INCAdam Fein

Founder & President
PEMBROKE CONSULTING INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country’s foremost experts on pharmacy economics and the pharmaceutical supply chain....

Samir Mehta

Orthopaedic Surgeon
Hospital of the University of Pennsylvania - CC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Samir Mehta, MD, is Orthopaedic Surgeon at the Hospital of the University of Pennsylvania. Previously, Dr. Mehta was Orthopaedic Surgeon and Assistant Professor of Orthopaedic Surgery in the Division of Orthopaedic Trauma at the University of Pennsylvania....

Walter Carlini

General Neurologist
Medford Neurological and Spine Clinic, Inc.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Walter Carlini, MD, PhD, is a General Neurologist at the Medford Neurological and Spine Clinic in Oregon. His clinical interests include stroke, epilepsy, migraine, dementia, movement disorders, and multiple sclerosis. Dr. Carlini has expertise in clinical...

View All Leading Experts in Healthcare

GLG Study Groups in Healthcare(?)

Study Group Name No. Members
Oncologists (US) 2240
Pharmacists (US) 2086
Obstetricians/Gynecologists 1953
Neurologists 1849
Pediatricians (US) 1693

View All Study Groups in Healthcare

GLG NewsSM Analyses in Healthcare(?)

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Legality and profitability can work

February 9, 2010

Superstore for medical marijuana supplies opens in Oakland | www.contracostatimes.com

Normally setting up a storefront office for the primary purpose of selling prescription to marijuana is a red flag for law enforcement officers and social movement groups.

Cetirizine OTC liquid. A day late and a dollar short.

February 8, 2010

Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC) | www.pipelinereview.com

Why the delay? Teva, Taro, and Perrigo all have strong footholds in this market. Rx and OTC competition remains strong, thus what would allow a new player to grow quickly outside of eroding the price market?

Victoza may be a large step forward

February 7, 2010

Novo Nordisk Receives US Approval For Victoza® (liraglutide) For The Treatment Of Type 2 Diabetes | www.medicalnewstoday.com

Victoza was approved at the end of January with head to head data already published vs. Byetta (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60659-0/abstract) showing greater reduction of fasting blood sugar, HbA1c, and weight with less nausea. This stands to both expand the GLP-1 market and take market from Amylin/Lilly until Byetta LAR reaches the market.

Advantage for Aurobindo Pharma - Approval of Cetirizine Hydrochloride Solution

February 7, 2010

Aurobindo Pharma receives final approval for Cetirizine Hydrochloride Solution (OTC) | www.pipelinereview.com

The launch of the Cetirizine Hydrochloride Solution will enhance Aurobindo Pharma's presence in the Asia. The launch of this OTC product will create significant advantage for Aurobindo Pharma.

XIAFLEX - A New Treatment for Dupuytren's Contracture

February 6, 2010

XIAFLEX release approved by FDA | www.xiaflex.com

Auxilium (and BioSpecifics Technologies) have finally received approval for release of XIAFLEX, the first FDA approved nonsurgical treatment for Dupuytren's Contracture. XIAFLEX is injected directly into the Dupuytren's cord and enzymatically disrupts the collagen. When successful, the contracture is released and range of motion is improved.

View All GLG News in Healthcare

Engage a member of GLG Healthcare councils

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
7 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software

GLG Clients have access to 65,000+ Healthcare Members Globally:

Healthcare Providers
33,000+
Healthcare Industry Experts
17,000+
Cardiologists
2,500+
Hospital Administrators
1,700+
Pharmacists
1,200+

Become a Council Member

GLG Research StudySM

245 U.S.-based neurologists share their opinion of Tysabri for the treatment of multiple sclerosis.

GLG Research Study: 245 Neurologists on Tysabri for MS

GLG Vital SignsSM

How will Revlimid's use change with this new data? How will Carfilzomib fit into a crowded market?

GLG Vital Signs: American Society of Hematology (ASH) Annual Meeting Recap: Revlimid and Carfilzomib Spotlight


Reactions from ten top medical oncologists, powered by the GLG Healthcare CouncilsSM, regarding data presented by Amgen and Bayer at the 34th European Society of Medical Oncology (ESMO) Congress in Berlin the week of September 21, 2009.

GLG Vital Signs: Post-ESMO Impact: Nexavar/Denosumab